For research use only. Not for therapeutic Use.
Talacotuzumab（Cat No.:I042201）is a monoclonal antibody that targets CD70, a cell surface protein often overexpressed in various cancers, including hematologic malignancies like acute myeloid leukemia (AML) and renal cell carcinoma (RCC). By binding to CD70, talacotuzumab is designed to activate immune-mediated tumor cell destruction. It also has the potential to deliver targeted cytotoxic effects, as CD70 is selectively expressed on cancer cells and certain immune cells. Currently, talacotuzumab is being investigated in clinical trials to assess its safety, efficacy, and potential as part of combination therapies for cancer treatment.
| CAS Number | 1826831-79-1 |
| Purity | ≥95% |
| Reference |
|
